Aclarion’s (ACON) Hold Rating Reiterated at Maxim Group

Maxim Group reissued their hold rating on shares of Aclarion (NASDAQ:ACON) in a research report released on Friday morning,Benzinga reports.

Separately, Ascendiant Capital Markets decreased their target price on shares of Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a research report on Wednesday, November 27th.

Aclarion Trading Down 7.9 %

ACON stock opened at $0.11 on Friday. Aclarion has a 1 year low of $0.10 and a 1 year high of $7.40. The stock’s fifty day moving average is $0.18 and its two-hundred day moving average is $0.23.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.